KLTO insider pledge: 2.0M shares pledged to Stock Loan Solutions for 3-year loan

Rhea-AI Filing Summary

Form 4 filing for Klotho Neurosciences, Inc. (KLTO) by Joseph Sinkule, CEO and Director. The filing reports two transactions: on 07/22/2025 and 08/05/2025 the Reporting Person transferred and pledged a total of 2,000,000 common shares to Stock Loan Solutions, LLC as collateral for a non-recourse, 3-year term loan. The lender may take actions with respect to the pledged shares, including selling, transferring, hedging, or creating and trading derivatives.

The report shows 4,446,700 shares beneficially owned following the 08/05/2025 transaction, which includes 1,000,000 shares issuable on incentive option exercise and 537,180 shares received as contingent merger consideration. The Reporting Person retains a conditional right to vote the pledged shares absent default; lender must transfer shares back within five business days of repayment, subject to setoff rights.

Positive

• Reporting Person retains conditional voting rights over pledged shares absent default
• Loan term explicitly stated as 3 years, providing a defined collateral timeline
• Beneficial ownership after transactions: 4,446,700 shares (explicitly disclosed)

Negative

• 2,000,000 shares pledged as collateral to Stock Loan Solutions, LLC for a non-recourse loan
• Lender may sell, assign, transfer, pledge, hypothecate, lend, hedge, or create derivatives with the pledged shares
• Lender may be deemed beneficial owner of pledged shares during the loan term and has setoff rights on repayment
• Proceeds intended to liquidate personal obligations, indicating insider liquidity use

Insights

Financial Analyst

TL;DR: CEO pledged 2.0M shares as collateral for a non-recourse 3-year loan; lender has broad disposition and hedging rights.

The pledge of 2,000,000 common shares by the CEO and Director is a material change in ownership structure reported on Form 4. The filing explicitly states the lender may sell, assign, transfer, pledge, hypothecate, lend, encumber, enter hedging arrangements, or create and trade derivative instruments backed by the shares. This creates potential near-term supply overhang risk and may affect market perception of insider liquidity needs, since proceeds are intended to liquidate personal obligations. The inclusion of 1,000,000 option-issuable shares in beneficial ownership and 537,180 contingent merger consideration should be tracked when modeling outstanding share count and dilution. Overall impact: negative due to pledge and lender rights.

Risk Analyst

TL;DR: Pledge grants lender broad rights and potential deemed beneficial ownership; conditional voting retained absent default.

From a governance and counterparty-risk perspective, the filing documents a non-recourse, 3-year loan secured by pledged shares and notes the lender may be deemed the beneficial owner during the loan term. The Reporting Person retains conditional voting rights absent default, and the lender must transfer shares back within five business days of repayment subject to setoff. These contractual mechanics raise counterparty and market-risk considerations: the lender's right to transfer or hedge the shares is explicit, and setoff rights could delay repatriation of shares. The disclosure signals increased insider leverage and is material and negative for shareholder dilution and governance monitoring.

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

SINKULE JOSEPH

(Last) (First) (Middle)

1300 SOUTH BOULEVARD SUITE D

(Street)

CHARLOTTE NC 28203

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
Klotho Neurosciences, Inc. [ KLTO ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	Chief Executive Officer

3. Date of Earliest Transaction (Month/Day/Year)
07/22/2025

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	07/22/2025		J		2,000,000	D	(1)(2)	3,909,520(3)	D
Common Stock	08/05/2025		A		537,180	A	(4)	4,446,700(3)	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

1. On July 22, 2025 and August 6, 2025, the Reporting Person transferred and pledged a total of 2,000,000 shares to Stock Loan Solutions, LLC ("Lender") as collateral for a non-recourse loan. The term of the loan is 3 years. The Reporting Person intends to use a portion of the proceeds from the term loan to liquidate some personal obligations. As beneficial owner of the shares pledged to it as collateral, Lender may take any and all actions with respect to such shares, including selling, assigning, transferring, pledging, hypothecating, lending, or encumbering the same, or enter into hedging arrangements, or create and trade derivative instruments backed by such shares as called for in the loan agreements.

2. Absent a default, the Reporting Person retains a conditional right to exercise the voting rights applicable to such shares. Within five business days of the Reporting Person's repayment of the loan, the Lender must transfer the Shares to the Reporting Person, subject to the Lender's right to withhold and set off against the Shares any sums owed to the Lender by the Reporting Person under the loan agreement. Despite the parties' intention for the Lender to transfer the Shares to the Reporting Person after the Loan is repaid, the Lender may be deemed to beneficially own the Shares during the Loan term.

3. Includes 1,000,000 shares issuable upon the exercise of incentive options.

4. The Reporting Person received the shares as contingent merger consideration.

Remarks:

	Joseph Sinkule	08/07/2025
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

FAQ

What did Joseph Sinkule (CEO) report on this KLTO Form 4?

The Form 4 discloses that Joseph Sinkule transferred and pledged a total of 2,000,000 common shares as collateral for a non-recourse, 3-year loan from Stock Loan Solutions, LLC.

How many shares does the reporting person beneficially own after the transactions?

The filing reports 4,446,700 shares beneficially owned following the reported transactions, which includes 1,000,000 option-issuable shares.

Can the lender trade or sell the pledged KLTO shares?

Yes. The filing explicitly states the lender may sell, assign, transfer, pledge, hypothecate, lend, encumber, enter into hedging arrangements, or create and trade derivative instruments backed by such shares.

What are the lender's transfer and setoff rights on repayment?

Within five business days of repayment, the lender must transfer the shares back to the Reporting Person, but may withhold or set off any sums owed by the Reporting Person under the loan agreement.

Why did the Reporting Person take the loan proceeds?

The Reporting Person stated the intention to use a portion of the loan proceeds to liquidate some personal obligations.